博九娱乐网

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive鈥檚 lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development…More for the treatment of acute kidney injury.